StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.12+0.04 (+0.66%)

Close on Nov 17, 2026Market cap $185.16MP/E –Yield –

Cartesian Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cartesian Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$78.61M. For fiscal 2025 it was -$79.40M. The highest annual figure on record is $34.07M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$79.40M–
FY2024Dec 31, 2024-$32.77M–
FY2023Dec 31, 2023-$51.37M–
FY2022Dec 31, 2022-$32.83M–
FY2021Dec 31, 2021-$61.47M-280.4%
FY2020Dec 31, 2020$34.07M–
FY2019Dec 31, 2019-$51.48M–
FY2018Dec 31, 2018-$60.05M–
FY2017Dec 31, 2017-$52.76M–
FY2016Dec 31, 2016-$20.34M–
FY2015Dec 31, 2015-$23.63M–
FY2014Dec 31, 2014-$12.91M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$21.35M–
Q1 FY2026Mar 31, 2026-$22.16M–
Q4 FY2025Dec 31, 2025-$18.20M–
Q3 FY2025Sep 30, 2025-$16.89M-325.5%
Q2 FY2025Jun 30, 2025-$20.12M–
Q1 FY2025Mar 31, 2025-$24.18M–
Q4 FY2024Dec 31, 2024-$7.71M–
Q3 FY2024Sep 30, 2024$7.49M–
Q2 FY2024Jun 30, 2024-$16.03M–
Q1 FY2024Mar 31, 2024-$16.52M–
Q4 FY2023Dec 31, 2023-$23.35M–
Q3 FY2023Sep 30, 2023-$9.22M-335.3%
Q2 FY2023Jun 30, 2023-$9.91M–
Q1 FY2023Mar 31, 2023-$8.90M–
Q4 FY2022Dec 31, 2022-$12.06M–
Q3 FY2022Sep 30, 2022$3.92M–
Q2 FY2022Jun 30, 2022-$12.37M–
Q1 FY2022Mar 31, 2022-$12.32M–
Q4 FY2021Dec 31, 2021-$31.74M–
Q3 FY2021Sep 30, 2021-$10.91M-116.7%
Q2 FY2021Jun 30, 2021-$6.66M–
Q1 FY2021Mar 31, 2021-$12.16M–
Q4 FY2020Dec 31, 2020-$7.44M–
Q3 FY2020Sep 30, 2020$65.35M–
Q2 FY2020Jun 30, 2020-$12.01M–
Q1 FY2020Mar 31, 2020-$11.83M–
Q4 FY2019Dec 31, 2019-$12.91M–
Q3 FY2019Sep 30, 2019-$11.13M–
Q2 FY2019Jun 30, 2019-$7.20M–
Q1 FY2019Mar 31, 2019-$20.24M–
Q4 FY2018Dec 31, 2018-$13.12M–
Q3 FY2018Sep 30, 2018-$16.09M–
Q2 FY2018Jun 30, 2018-$17.24M–
Q1 FY2018Mar 31, 2018-$13.60M–
Q4 FY2017Dec 31, 2017-$12.81M-1032.3%
Q3 FY2017Sep 30, 2017-$15.56M–
Q2 FY2017Jun 30, 2017-$9.02M–
Q1 FY2017Mar 31, 2017-$15.37M–
Q4 FY2016Dec 31, 2016$1.37M–
Q3 FY2016Sep 30, 2016-$5.74M–

More Cartesian Therapeutics figures

See a number that looks wrong?